Nuformix plc (FRA:1RT)

Market Cap	5.02M +181.3%
Revenue (ttm)	n/a
Net Income	-712.91K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0020
Previous Close	0.0020
Day's Range	0.0020 - 0.0020
52-Week Range	0.0005 - 0.0190
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 3, 2026

About Nuformix

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NX...

• Industry: Pharmaceutical Preparations
• Founded: 2008
• Employees: 3
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1RT

Financial Performance

Financial numbers in GBP

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error